Wang, Ying
Wu, Depei
Zhang, Xiang
Li, Yuhua
He, Yanjie
Liu, Qifa
Xuan, Li
Li, Zhenyu
Qi, Kunming
Sun, Yuqian
Wang, Shunqing
Mo, Wenjian
Gao, Lei
Hua, Ye
Wang, Yu
Zhang, Ying
Funding for this research was provided by:
BioNova Pharmaceuticals (Shanghai) Limited
Article History
Received: 11 October 2023
Accepted: 11 March 2024
First Online: 26 March 2024
Declarations
:
: The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines from the International Conference on Harmonisation, and local applicable regulatory requirements. All procedures were approved by the institutional review boards/independent ethics committee at the leading site (First Affiliated Hospital of Soochow University) and participating institutions. The approval number for each ethics committee is listed below. All patients provided written informed consent prior to screening.The First Affiliated Hospital of Soochow University: (2020) Ethics approval No. 098Peking University People’s Hospital: 2021PHA025-001Xinqiao Hospital of Army Medical University: 2021-Medical number 003-01The Affiliated Hospital of Xuzhou Medical University: XYFY2021-YL030-01Nanfang Hospital: NFEC-2021-113Zhujiang Hospital, Southern Medical University: 2021-YW-017–01Guangzhou First People’s Hospital: A-2021–023-01
: Not applicable.
: YH, YW, and YZ are employees of BioNova Pharmaceuticals (Shanghai) Limited. YH holds BioNova Pharmaceuticals (Shanghai) Limited stocks and options. All other authors declare that they have no competing interests.